Abstract
The R-isomer of ISO-1, a 3,5-disubstituted Δ 2-isoxazoline, has been implicated as a potential therapeutic agent for the treatment of Type 1 Diabetes via the antagonism of macrophage migration inhibitory factor (MIF). Δ 2-Isoxazolines can be prepared by the palladium(II)-mediated cyclization of substituted β,γ-unsaturated oximes. While this reaction results in racemic mixtures, we have developed a stereoselective variant of this method based on the incorporation of an enantiomeric palladium complex in the reaction mixture. The use of chiral bisoxazoline ligands in the palladium(II)-mediated ring closure reaction has been shown to enhance the enantiomeric excess due to chirality at C5 of the Δ 2-isoxazoline.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
